Lgnd stock zacks

Oct 29, 2019 · LGND, Ligand Pharmaceuticals - Stock quote performance, technical chart analysis, Ligand Pharmaceuticals (LGND) - DEVELOPS PHARMACEUTICALS IN THE AREAS OF ONCOLOGY, CENTRAL NERVOUS SYSTEM, INFLAMMATION, Zacks Equity Research 03/07/2020 05:30 AM ET. LGND vs. ALKS: Which Stock Is the Better Value Option? Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Ligand Pharmaceuticals (LGND) and Alkermes (ALKS). But which of these two stocks presents… As your browser does not support javascript you won't be able to use all the features of the website.

Ligand (LGND) Q4 Earnings & Revenues Top Estimates ... Ligand Pharmaceuticals Incorporated LGND reported fourth-quarter 2019 adjusted earnings of 71 cents per share, which beat the Zacks Consensus Estimate of 68 cents. The company had reported adjusted earnings of $1.70 in the year-ago quarter. Fourth-quarter adjusted earnings exclude the impact of non-cash charge of $8.5 million related to Ligand's investment in Viking Therapeutics, stock-based LGND - Ligand Pharmaceuticals Incorporated Summary, Stock ... Jan 01, 2010 · Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) stock research, profile, news, analyst ratings, key statistics, fundamentals, stock price, charts, earnings

Zacks: Analysts Anticipate Ligand Pharmaceuticals Inc ...

Ligand's (LGND) Q3 Earnings Miss Estimates, EPS View Down Nov 06, 2019 · Ligand Pharmaceuticals Incorporated LGND reported third-quarter 2019 adjusted earnings of 49 cents per share, which missed the Zacks Consensus Estimate of … Zacks.com highlights: Michael Kors Holdings, Ligand ... Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing Ligand (LGND) Surges: Stock Moves 6.3% Higher Sep 13, 2019 · Ligand Pharmaceuticals Incorporated LGND was a big mover last session, as the company saw its shares rise more than 6% on the day. The move came on … Zacks.com featured highlights include: Catabasis, Ligand ...

Ligand (LGND) Stock Down Despite Q2 Earnings & Sales ...

Zacks.com featured highlights include: Catabasis, Ligand ... Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of … Zacks.com featured highlights include: Ligand, Energy ... Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of … Ligand (LGND) Stock Down Despite Q2 Earnings & Sales ... Jul 31, 2019 · Ligand Pharmaceuticals Incorporated LGND reported second-quarter 2019 adjusted earnings of 68 cents per share, which beat the Zacks Consensus Estimate of 61 cents. The company had reported adjusted earnings of $2.59 in the year-ago quarter. Second-quarter adjusted earnings exclude the impact of non-cash charge of $12.4 million related to Ligand's investment in Viking Therapeutics, stock … LGND | Ligand Pharmaceuticals Inc. Profile | MarketWatch

All News for LGND - Zacks Investment Research

Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of … Zacks.com featured highlights include: Ligand, Energy ... Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of … Ligand (LGND) Stock Down Despite Q2 Earnings & Sales ...

Zacks.com featured highlights include: Catabasis, Ligand ...

This ETF offers broad exposure to the U.S. equity market, investing in thousands of different securities across all sectors. That makes VTI an appealing option for  LGND - Zacks Investment Research Get the latest Ligand Pharmaceuticals Incorporated LGND detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Ligand Pharmaceuticals Incorporated - LGND - Stock Price Today - Zacks All News for LGND - Zacks Investment Research by Zacks Equity Research Published on February 06,2020 . Ligand (LGND) delivered earnings and revenue surprises of 4.41% and 8.27%, respectively, for the quarter ended December 2019. LGND: Ligand Pharmaceuticals Incorporated - Price ...

Ligand Pharmaceuticals Incorporated (LGND) Stock Analysis ... Get breaking news and analysis on Ligand Pharmaceuticals Incorporated (LGND) stock, price quote and chart, trading and investing tools. at Zacks.com (Mar 7, 2020) Ligand Pharmaceuticals Incorporated Common Stock (LGND ...